Britain and America have hammered out a landmark trade agreement that will keep no import taxes on British pharmaceutical exports going into the US market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has agreed to boost expenditure on medicines through the National Health Service (NHS). This move guarantees that import taxes on these key products will remain at zero for a period of three years.
This development follows previous statements to dramatically increase import taxes on patented drug products, with figures floated as high as double the cost.
"This deal between the Britain strengthens the worldwide climate for innovative medicines and introduces much-needed equity to U.S.–U.K. medicine commerce," an announcement said.
Economic Importance
Medicines constitute one of the UK's biggest goods shipped to the United States, which is clearly the biggest buyer for large UK drugmakers.
Export figures reveal that in the year to the end of last September, the UK exported pharmaceutical products valued at £11.1bn to the US. This figure represented nearly one-fifth of all goods exports in that span.
"This deal secures employment, boosts investment and facilitates the UK to become a international leader for life sciences," a minister stated.
Detailed British Pledges
The deal includes several specific commitments from the British government:
- Higher Cost Ceiling: The UK will lift the price threshold at which it deems new therapies to be too expensive by a quarter.
- Boosted Medicine Funding: There is a goal to double total NHS spending on drugs from 0.3 percent of GDP to 0.6 percent over the next decade.
- Rebate Cap: The sum drug companies must pay back to the NHS to prevent overspending will be restricted at 15%. Previously, refunds topped 20%.
Broader Context
This agreement comes amid a ongoing dispute between the sector and the British authorities over drug pricing and NHS adoption.
These tensions were exacerbated by claims that American consumers were paying significantly more for the same drugs than people in the Britain and the EU.
In recent months, several major drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar investments have been announced toward projects in the United States.
A senior figure stated that the NHS needed to invest a greater share on drugs, noting that its budget allocation on drugs had shrunk as a proportion of its resources over the previous ten-year period.
